EU/3/16/1715

About

On 29 August 2016, orphan designation (EU/3/16/1715) was granted by the European Commission to Athena Vision Ltd, United Kingdom, for adenovirus-associated viral vector serotype 5 containing the human RPGR gene for the treatment of retinitis pigmentosa.

In September 2016, Athena Vision Ltd changed name to MeiraGTx UK II Limited.

The sponsorship was transferred to MeiraGTx B.V., The Netherlands in May 2019.

Key facts

Active substance
Adenovirus-associated viral vector serotype 5 containing the human RPGR gene
Disease / condition
Treatment of retinitis pigmentosa
Date of first decision
29/08/2016
Outcome
Positive
EU designation number
EU/3/16/1715

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

MeiraGTx B.V.
Robert Boyleweg 4
2333 CG Leiden
Zuid-Holland
The Netherlands
Tel. +31 (0) 6480 67303
E-mail: info@meiragtx.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating